Literature DB >> 16721492

Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.

Guzide Aksu1, Can Ozturk, Kaan Kavakli, Ferah Genel, Necil Kutukculer.   

Abstract

Familial Mediterranean fever (FMF) patients in clinical remission are reported to have increased baseline inflammation. Normal function of the natural anticoagulant pathways is particularly needed in diminishing inflammatory responses. In the presence of subclinical inflammation, natural anticoagulant response may be exaggerated. We aimed to observe the anticoagulant-procoagulant status in attack-free FMF patients. Twenty-seven FMF patients diagnosed in accordance with Tel-Hashomer criteria, and 26 healthy controls were included. All patients were attack-free under regular colchicine treatment. Amyloidosis, autoimmunity, accompanying liver and renal disease, and vasculitis were excluded. Predisposing factors for thrombosis were not present. Acute phase reactants (APRs), anticardiolipin antibody positivity, prothrombin time (PT), activated prothrombin time, thrombin time (TT) and d-dimer, protein C activity, activated protein C resistance, free protein S, antithrombin, lupus anticoagulant, human prothrombin fragment F 1 + 2, and human thrombin/antithrombin III complex were analyzed for all subjects. APRs were comparable with controls. Autoimmune markers were negative in all. Anti-streptolysin titers were significantly different than the control group. PT, TT, protein C activity, and F 1 + 2 levels were significantly different from those of healthy controls. Shortened PT and TT, decreased protein C activity vs increased levels of F 1 + 2 suggested a hypercoagulable state in our patients. The hypercoagulable state detected in FMF patients suggests that screening with abnormal coagulation tests may be beneficial for tracing the future consequences of subclinical inflammation in these patients. Studies covering larger groups of patients are needed to verify the currently observed hypercoagulable status in FMF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721492     DOI: 10.1007/s10067-006-0334-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Frequency of Factor V (1691 G --> A) mutation in Turkish population.

Authors:  N Akar; E Akar; G Dalgin; A Sözüöz; K Omürlü; S Cin
Journal:  Thromb Haemost       Date:  1997-12       Impact factor: 5.249

2.  Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.

Authors:  K Johnson; Y Choi; E DeGroot; I Samuels; A Creasey; L Aarden
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

3.  Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci.

Authors:  N Ruiz; B Wang; A Pentland; M Caparon
Journal:  Mol Microbiol       Date:  1998-01       Impact factor: 3.501

Review 4.  Role of coagulation inhibitors in inflammation.

Authors:  C T Esmon
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

5.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  New compact-type latex photometric immunoassay system for hemoglobin and three acute inflammation markers: neutrophil count, C-reactive protein, and anti-streptolysin O.

Authors:  Tatsuo Fukumori; Hironobu Ohta; Akio Okubo; Masayuki Hino; Kensuke Ohta; Takahisa Yamane; Noriyuki Tatsumi
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

8.  Antistreptococcal response is exaggerated in children with familial Mediterranean fever.

Authors:  F Yalçinkaya; E Ince; T Uçar; N Ozkaya; M Tekin; A H Elhan; E Tutar; D H Güriz; D Aysev; R Gökdemir; U Doğru; N Tümer
Journal:  Clin Rheumatol       Date:  2002-09       Impact factor: 2.980

Review 9.  Management of thrombophilia.

Authors:  K A Bauer
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

10.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

View more
  14 in total

Review 1.  Familial Mediterranean fever and atherosclerosis in childhood and adolescence.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2019-11-08       Impact factor: 2.631

2.  Is Familial Mediterranean Fever a thrombotic disease or not?

Authors:  Atalay Demirel; Tiraje Celkan; Ozgur Kasapcopur; Hulya Bilgen; Alp Ozkan; Hilmi Apak; Nil Arisoy; Inci Yildiz
Journal:  Eur J Pediatr       Date:  2007-04-14       Impact factor: 3.183

Review 3.  Coexistence of vasculitides with familial Mediterranean fever.

Authors:  Kenan Aksu; Gokhan Keser
Journal:  Rheumatol Int       Date:  2011-03-10       Impact factor: 2.631

Review 4.  Non-canonical manifestations of familial Mediterranean fever: a changing paradigm.

Authors:  Donato Rigante; Giuseppe Lopalco; Giusyda Tarantino; Adele Compagnone; Michele Fastiggi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-03-13       Impact factor: 2.980

5.  Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation.

Authors:  Sahru Yüksel; Lilit Ayvazyan; Armen Yuri Gasparyan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

6.  Evaluation of circulating endothelial biomarkers in familial Mediterranean fever.

Authors:  Baris Onder Pamuk; Ismail Sari; Sema Selcuk; Goksel Gokce; Didem Leyla Kozaci
Journal:  Rheumatol Int       Date:  2013-01-29       Impact factor: 2.631

Review 7.  Cardiac disease in familial Mediterranean fever.

Authors:  Eren Erken; Ertugrul Erken
Journal:  Rheumatol Int       Date:  2017-10-20       Impact factor: 2.631

8.  Familial mediterranean Fever and hypercoagulability.

Authors:  Oshrat E Tayer-Shifman; Eldad Ben-Chetrit
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-16       Impact factor: 2.576

9.  Autoinflammatory diseases: a possible cause of thrombosis?

Authors:  Micaela La Regina; Francesco Orlandini; Raffaele Manna
Journal:  Thromb J       Date:  2015-05-12

10.  Extensive thrombosis in a patient with familial Mediterranean fever, despite hyperimmunoglobulin D state in serum. [corrected].

Authors:  Kowoon Joo; Won Park; Moon-Hyun Chung; Mie-Jin Lim; Kyong Hee Jung; Yoonseok Heo; Seong-Ryul Kwon
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.